Request Demo

Last update 04 Nov 2025

Atezolizumab

Last update 04 Nov 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-PDL-1-Genentech/Roche, Atezolizumab (Genetical Recombination), Atezolizumab (genetical recombination) (JAN)

+ [11]

Target

PDL1

Action

inhibitors

Mechanism

PDL1 inhibitors(Programmed death-ligand 1 inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [11]

Active Indication

Advanced Lung Non-Small Cell CarcinomaBreast CancerAlveolar Soft Part Sarcoma+ [163]

Inactive Indication

Adenocarcinoma of large intestineAdvanced Bile Duct CarcinomaAdvanced biliary tract cancer+ [82]

Originator Organization

Genentech, Inc.Universitair Medisch Centrum Groningen

Active Organization

Hoffmann-La Roche, Inc.Roche Registration GmbH

Genentech, Inc.

+ [24]

Inactive Organization

Affimed GmbH

Sanofi

Basilea Pharmaceutica AG

+ [8]

License Organization

NeoImmuneTech, Inc.

Harpoon Therapeutics, Inc.Novocure, Inc.

+ [26]

Drug Highest PhaseApproved

First Approval Date

United States (18 May 2016),

Transitional Cell Carcinoma

RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Orphan Drug (Australia), Priority Review (Australia), Conditional marketing approval (China), Orphan Drug (Japan)

Structure/Sequence

Sequence Code 122091L

Source: *****

Sequence Code 4720027H

Source: *****

880

Clinical Trials associated with Atezolizumab

NCT07155174

/ Not yet recruitingPhase 2/3

A Phase 2 Randomized, Open Label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Subjects With Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).
ABBV-706 is an investigational drug being developed for the treatment of SCLC. There are multiple treatment arms in this study. Participants will either receive ABBV-706 given with atezolizumab, at 1 of 2 doses, or SOC. Approximately 180 adult participants will be enrolled in the study across sites worldwide.
In the safety lead-in, participants with SCLC will receive intravenous (IV) ABBV-706 in 1 of 2 doses with IV atezolizumab, or IV SOC. In the expansion portion of the study, participants with SCLC will receive IV ABBV-706 in 1 of 2 doses with atezolizumab, or IV SOC, until the optimal dose of ABBV-706 is determined. The estimated duration of the study is up to 69.5 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

Start Date06 Dec 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06680258

/ Not yet recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy

The goal of this clinical trial is to determine if TPST-1120 in combination with atezolizumab and bevacizumab helps patients to live longer compared to atezolizumab and bevacizumab alone (the standard of care treatment) in adult patients with hepatocellular carcinoma that cannot be removed by surgery or has spread outside of the liver (called metastatic). The trial also will study the safety and side effects of the drug combination compared to the standard of care treatment. Other questions the trial aims to answer include:
1. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the time that patients are alive and cancer is not growing (progression free survival) compared to atezolizumab and bevacizumab
2. Does TPST-1120 in combination with atezolizumab and bevacizumab improve the shrinking of cancer (the overall response rate) compared to atezolizumab and bevacizumab
Trial participants will be randomly assigned to take one of the following:
1. TPST-1120 3 tablets (600 mg) by mouth twice a day every day along with atezolizumab 1200 mg intravenously every 3 weeks and bevacizumab 15 mg/kg intravenously every 3 weeks
2. Placebo (look-alike that does not contain study drug) 3 tablets by mouth twice a day every day along with atezolizumab 1200 mg intravenously once every 3 weeks and bevacizumab 15 mg/kg intravenously once every 3 weeks
Trial participants will receive routine and trial-specific cancer care from their study doctor including
* visits to the clinic every 3 weeks for physical examination, labs and questions about health and symptoms
* measurement of their cancer by CT scan every 9 weeks.
Trial participants can stop study treatment at any time they choose and for any reason. They also can continue to receive study treatment for as long as the treatment is controlling cancer growth and they are tolerating the drug effects.

Start Date01 Dec 2025

Sponsor / Collaborator

Tempest Therapeutics, Inc.

NCT07049848

/ Not yet recruitingPhase 2IIT

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

The goal of this clinical research study is to look at the effectiveness of giving a combination of chemotherapy, immunotherapy, radiation therapy, and surgery to treat soft tissue sarcomas that can be removed by surgery. Researchers want to find out if this treatment combination can extend the time it takes for the disease to relapse (come back after treatment). The safety of this treatment combination will also be studied.

Start Date01 Dec 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

[+1]

100 Clinical Results associated with Atezolizumab

100 Translational Medicine associated with Atezolizumab

100 Patents (Medical) associated with Atezolizumab

4,577

Literatures (Medical) associated with Atezolizumab

01 Apr 2026·DEN open

A Rare Case of Immune‐related Adverse Events Localized to the Small Intestine

Article

Author: Morikawa, Ryo ; Taguchi, Towako ; Fukuda, Masayoshi ; Okamoto, Ryuichi ; Fujii, Toshimitsu ; Kanaya, Ryosuke ; Nemoto, Yasuhiro ; Yamamoto, Kurara ; Ohtsuka, Kazuo ; Shimizu, Hiromichi

ABSTRACT:

Enterocolitis is a common gastrointestinal manifestation of immune‐related adverse events (irAEs); however, only a few studies have reported on irAE enteritis with localized active inflammation in the small intestine. Here, we report the case of a 74‐year‐old man who developed diarrhea, abdominal pain, and oral intake difficulty and was subsequently hospitalized after receiving atezolizumab for pulmonary adenocarcinoma. Computed tomography and enterocolonoscopy revealed active inflammation in the small intestine but not in the colon, leading to the final diagnosis of irAE enteritis. After initiating prednisolone at a dose of 60 mg/day, his symptoms improved rapidly, and a follow‐up enterocolonoscopy revealed a marked reduction in inflammation. Being a relatively rare gastrointestinal toxicity, irAE enteritis often goes unrecognized due to diagnostic challenges, but can lead to serious AEs such as perforation. Therefore, even if colonoscopy findings are normal, a thorough examination of the small intestine is essential for patients who develop gastrointestinal symptoms while undergoing immune checkpoint inhibitor therapy. We herein report a rare case of irAE enteritis confirmed through endoscopic and pathological examination, which has not been previously reported.

01 Apr 2026·DEN open

A Case of Obstructive Jaundice due to Bile Duct Tumor Thrombus of Hepatocellular Carcinoma Diagnosed by Peroral Cholangioscopy

Article

Author: Tokumaru, Tomoko ; Endo, Mizuki ; Kinoshita, Keisuke ; Uchida, Takuro ; Murakami, Kazunari ; Okamoto, Kazuhisa ; Saito, Tomoko ; Kodama, Masaaki ; Iwao, Masao ; Arakawa, Mie

Abstract:

While hepatocellular carcinoma (HCC) often invades the portal or hepatic vein to form tumor thrombus, tumor thrombus in the bile duct is rare. In such cases, differentiation from intrahepatic cholangiocarcinoma is difficult, and the tumor often appears as a smooth, yellowish‐white, polypoid mass within the bile duct lumen. We report herein a case of obstructive jaundice due to bile duct tumor thrombus of HCC diagnosed by peroral cholangioscopy (POCS). A 64‐year‐old man presented with epigastralgia and jaundice. Contrast‐enhanced computed tomography revealed an irregular mass with hypoenhancement in liver segment S8, along with dilatation of the right intrahepatic bile duct due to the invading tumor. The hepatic mass was poorly visualized on ultrasound, making percutaneous liver tumor biopsy difficult. POCS was performed after endoscopic retrograde cholangiopancreatography for biopsy of the intrahepatic bile duct tumor thrombus. POCS clearly revealed a smooth, yellowish‐white, polypoid tumor in the right intrahepatic bile duct, and a biopsy of the tumor was performed under POCS. Based on the pathological findings, HCC was diagnosed, and chemotherapy with atezolizumab and bevacizumab was initiated.

01 Jan 2026·Value in Health Regional Issues

Real-World Effectiveness and Cost-Utility Analysis of Second-Line Immunotherapy for Non-Oncogene-Addicted Advanced Non-Small Cell Lung Cancer

Article

Author: Preedachitkul, Rinrada ; Chitpim, Natthakan ; Khunakorncharatphong, Anon ; Thamlikitkul, Lucksamon ; Horugsa, Chulamas ; Sawasdisara, Sasiporn ; Srinonprasert, Varalak

OBJECTIVES:

To determine the cost-effectiveness of second-line immune checkpoint inhibitors (ICIs) compared with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) using real-world patient-level treatment effectiveness, cost, and utility data.

METHODS:

Medical records of patients with NSCLC receiving second-line ICIs or chemotherapy at Siriraj Hospital, Bangkok, Thailand from January 2016 to May 2023 were reviewed to evaluate treatment effectiveness and direct medical costs. Patients receiving treatment from July 2023 to March 2024 were interviewed to determine utility and direct nonmedical costs. A semi-Markov model was used to analyze the lifetime costs and health outcomes from societal perspective. One-way and probabilistic sensitivity analyses and scenario analyses were performed.

RESULTS:

Data were collected from 209 patients (72 and 137 patients received second-line ICIs and chemotherapy, respectively). Second-line ICIs significantly improved overall survival (hazard ratio 0.64, 95% confidence interval 0.47-0.89, P = .008) and increased the quality-adjusted life-years (QALYs) from 0.54 to 1.11, resulting in QALY gain of 0.57; lifetime cost increased from 17 204 US dollar (USD) to 34 424 USD. Second-line ICI incremental cost-effectiveness ratio was 30 104 USD/QALY. Scenario analysis revealed that second-line ICIs were more cost-effective than chemotherapy for healthier patients (Eastern Cooperative Oncology Group 0-1) with incremental cost-effectiveness ratio of 9856 USD/QALY. Considering Thailand's willingness-to-pay threshold of 4444 USD/QALY, second-line ICIs could be cost-effective if the cost of atezolizumab was reduced by 86%.

CONCLUSION:

Second-line ICIs significantly improved survival in advanced NSCLC but are not cost-effective in Thailand. Drug price negotiation and patient subgroup prioritization would help make second-line ICIs more accessible.

1,503

News (Medical) associated with Atezolizumab

31 Oct 2025

·www.globenewswire.com

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here. Chris Cargill, President and CEO of Nxera, commented: “During the third quarter of 2025, we made strong progress in advancing our plans for obesity and metabolic diseases, an area of strategic focus where we see exceptional opportunity and have observed significant patient need. Our newly launched proprietary pipeline, led by our differentiated oral GLP-1 agonist and including multiple complementary GPCR-targeted programs, positions Nxera to play a leading role in shaping the next generation of metabolic therapies. “Meanwhile, our partnered programs continue to advance successfully with multiple milestones achieved across ongoing collaborations, notably with Centessa and its portfolio of orexin agonists, where there is growing industry interest in the orexin mechanism as a promising basis for novel therapies for sleep-wake disorders and other neurological conditions. These candidates were discovered using NxWave™ technology, reflecting the strength and versatility of our platform to generate novel molecules with potential to make meaningful therapeutic advances for patients. We also achieved a second important R&D milestone under our multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera. With this progress and a robust pipeline of data and milestones ahead, we are well positioned to close the year with strong momentum.” Operational Highlights for Q3 2025 Launch of proprietary pipeline targeting obesity and chronic weight management, led by an oral small molecule GLP-1 agonist and six additional GPCR-targeted programs Programs leverage Nxera’s NxWave™ structure-based design platform to advance differentiated small molecules aimed at optimizing metabolic efficacy, sustaining weight reduction, and preserving lean mass. First patient dosed in Phase 2a trial of investigational cancer immunotherapy HTL0039732 HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK’s Centre for Drug Development is sponsoring and managing the ongoing trial Second R&D milestone reached under Nxera’s multi-target discovery collaboration with AbbVie, resulting in a payment of US$10 million to the Company Collaboration aims to leverage Nxera’s NxWave™ platform to discover, develop and commercialize new medicines targeting novel GPCR targets associated with neurological disease Post-period events Nxera’s partner Cancer Research UK presented data from the successfully completed Phase 1 clinical trial of HTL’732 at the European Society for Medical Oncology Congress (ESMO) 2025 HTL’732 was well-tolerated, confirmed target engagement and demonstrated encouraging early efficacy in two distinct tumor types when administered in combination with atezolizumabThe Phase 1 trial met the key objectives and identified a dose for the Phase 2 expansion trial which is now underway Manufacturing approval partial amendment from Japan’s Ministry of Health, Labour and Welfare for an additional manufacturing site in Asia for QUVIVIQ 25 and 50mg Expected to improve profitability through manufacturing cost reductions to advance toward 2030 vision Financial Highlights for the Nine-month Period ended 30 September 2025 Revenue totalled JPY 21,848 million (US$147.4 million*), a decrease of JPY 135 million (an increase of US$2.0 million) vs. the prior corresponding period. The decrease was due to the smaller size of individual milestone receipts compared to the prior corresponding period, despite there being more milestone events: there were six milestone events in the period under review vs. five milestone events in the prior corresponding period. This reduction is partially offset by the inclusion of sales of QUVIVIQ® following its launch in the fourth quarter of 2024. R&D expenses totalled JPY 11,200 million (US$75.6 million), an increase of JPY 2,683 million (US$19.2 million) vs. the prior corresponding period. This increase primarily reflects an increased investment in R&D and the impact of the weaker Yen.SG&A expenses totalled JPY 11,410 million (US$77.0 million), a decrease of JPY 307 million (US$0.5 million) vs. the prior corresponding period. This decrease was primarily due to lower selling related costs as a result of targeted cost savings, partially offset by incremental spend on personnel to strengthen organizational capabilities.Operating loss totalled JPY 5,907 million (US$39.9 million) vs. an operating loss of JPY 2,846 million (US$18.8 million) in the prior corresponding period. This change in profitability reflects the combined effect of all movements explained above.Loss before income tax totalled JPY 6,838 million (US$46.1 million) vs. a loss before income tax of JPY 2,293 million (US$15.2 million) in the prior corresponding period.Net loss totalled JPY 4,809 million (US$32.5 million) vs. a net loss of JPY 3,503 million (US$23.2 million) in the prior corresponding period.Core operating loss** totalled JPY 986 million (US$6.6 million) vs. a core operating profit of JPY 4,425 million (US$29.3 million) in the prior corresponding period. Cash and cash equivalents as at 30 September 2025 amounted to JPY 28,461 million (US$191.5 million) having decreased by JPY 3,807 million (US$14.3 million) from the beginning of the year. *Convenience conversion to US$ at the following rates: FY 2025: 1US$ =148.18 JPY; FY 2024: 1US$ =151.14 JPY; 30 Sep 2025: 1US$ = 148.60 JPY; 31 Dec 2024: 1US$ = 156.83 JPY ** Core operating profit / loss is an alternative performance measure which adjusts for material non-cash costs and one-off costs in order to provide insights into the recurring cash generation capability of the core business. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@medistrava.com Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Attachment Nxera Pharma _ FY25Q3_Tanshin

Phase 2Phase 1Financial StatementImmunotherapy

30 Oct 2025

·endpoints.news

Bristol Myers tries to temper anxiety over upcoming Cobenfy readout, unveils suite of PD-1xVEGF bispecific trials

Bristol Myers Squibb didn’t reveal anything earth-shattering in its third-quarter earnings report on Thursday, but rather a handful of smaller updates on its pipeline and negotiations with the Trump administration. And analysts appeared most interested in an upcoming readout for Cobenfy in Alzheimer’s disease psychosis — expected before the end of the year — and expressed a growing level of anxiety. Earlier this year, Cobenfy failed a Phase 3 study as an adjunctive treatment for schizophrenia, and former CMO Samit Hirawat last quarter said the company would be conducting trial site reviews for the upcoming psychosis data. On Thursday’s call, CEO Chris Boerner tried to assuage concerns, reiterating that the data are on track for the end of 2025. When asked, he declined to provide specifics on why the data haven’t come out yet and whether or not Bristol Myers is seeing any irregularities at the trial sites under review. “We obviously understand there’s a lot of focus on individual programs, including the ones that are going to be reading out most near-term,” Boerner said. “So I wouldn’t read too much into it, other than to say that there’s a lot of focus on us being able to deliver on each of the stages of our strategy.” Although Cobenfy was approved for schizophrenia last year, Bristol Myers is hoping to expand its label to a number of Alzheimer’s-adjacent indications, including psychosis, agitation and cognition. In addition to this year’s readout, BMS is expecting two other Alzheimer’s psychosis trials to have data next year. The company has said two of the three studies need to be positive in order to seek approval. Executives have previously portrayed these as key to growing Cobenfy into a megablockbuster. BMS is also studying Cobenfy in multiple bipolar disorder settings. Bristol Myers also revealed a number of new trials where it would be testing its PD-1xVEGF bispecific pumitamig. Working with BioNTech, the companies are launching studies in triple-negative breast cancer, colorectal cancer and gastric cancer. Notably, the colorectal cancer study is in the microsatellite-stable setting, an area where industry experts have thought bispecifics could make a big impact and where PD-1 checkpoint inhibitors previously proved ineffective. Chief commercialization officer Adam Lenkowsky said the company’s strategy is to be the “first or second” bispecific approved. Bristol Myers’ main competition is Summit Therapeutics, which earlier this month announced its first trial outside lung cancer — and also in microsatellite-stable colorectal cancer. “Our focus is on speed to market,” Lenkowsky said. “We feel very good about combining our industry-leading commercial and operational capabilities with BioNTech’s scientific expertise. We plan to maximize the potential of this asset.” Here’s the full outline for BMS’ pumitamig studies, all of which are in the first-line setting: Also during Thursday’s Q&A with analysts, Boerner provided perhaps the most in-depth commentary so far on how negotiations with the Trump administration are going. Boerner said that while BMS and the administration don’t agree on every minute detail, the conversations have been constructive and frequent on issues like most favored nation pricing. “While not always fully aligned, they’re always constructive and thought-provoking on both sides,” Boerner said. “Clearly, MFN and tariffs are front and center, but we continue to monitor a host of other issues, including the shutdown and what potential impact that could have downstream. “All of that for us, though, is that we agree with the president on the need for equalization of prices. US prices need to come down,” he continued. “Ex-US prices need to come up. We’ve seen some good progress, for example, in the UK. But more needs to be done. And accomplishing those objectives while preserving the ecosystem for innovation that we have in the US is what we’re focused on. “So there’s a lot going on. It’s manageable.”

Phase 3

30 Oct 2025

·ir.xiliotx.com

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting

WALTHAM, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will present a late-breaking poster presentation for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place from November 5-9, 2025 in National Harbor, Maryland. The Phase 2 data will highlight response rate for vilastobart in combination with atezolizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) and high plasma tumor mutational burden. Poster presentation details are as follows: Abstract Title: Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab in Patients with Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) Late-Breaking Abstract Number: 1315 Presentation Date: Friday, Nov. 7, 2025 Poster Hall Hours: 9:00 a.m.-7:00 p.m. EST Location: Prince George ABC Exhibit Halls Gaylord National Resort and Convention Center Gaylord The poster will be available on November 7, 2025 under the “Our Approach—Presentations & Publications” section of the Xilio Therapeutics website at www.xiliotx.com. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present data related to Xilio’s clinical program for vilastobart; and Xilio’s strategy, goals and anticipated financial performance, milestones, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio’s ability to advance multiple early stage masked T cell engager programs; initial, preliminary or interim preclinical or clinical data or results may not be replicated in or predictive of future preclinical or clinical data or results; Xilio’s ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio’s product candidates may not support further development of such product candidates; actions of regulatory agencies may affect the initiation, timing and progress of current or future clinical trials; Xilio’s ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio’s need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; and Xilio’s ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the U.S. Securities and Exchange Commission (“SEC”), including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Investor Contact  Alex Lobo, Precision AQ alex.lobo@precisionaq.com Media Contact  Josie Butler, 1AB josie@1abmedia.com

ImmunotherapyPhase 2ASCO

100 Deals associated with Atezolizumab

External Link

KEGG	Wiki	ATC	Drug Bank
D10773	Atezolizumab	L01XC32	DB11595

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Advanced Lung Non-Small Cell Carcinoma	European Union	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Iceland	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Liechtenstein	Roche Registration GmbH	25 Jul 2024
Advanced Lung Non-Small Cell Carcinoma	Norway	Roche Registration GmbH	25 Jul 2024
Breast Cancer	Canada	F. Hoffmann-La Roche Ltd.	13 Mar 2024
Alveolar Soft Part Sarcoma	United States	Genentech, Inc.	09 Dec 2022
PD-L1 positive Non-Small Cell Lung Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	26 May 2022
BRAF V600 mutation-positive Melanoma	United States	Genentech, Inc.	30 Jul 2020
PD-L1 positive Triple Negative Breast Cancer	Japan	Chugai Pharmaceutical Co., Ltd.	19 Jan 2018
Advanced Hepatocellular Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Hepatocellular Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	European Union	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Iceland	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Liechtenstein	Roche Registration GmbH	20 Sep 2017
Advanced Triple-Negative Breast Carcinoma	Norway	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	European Union	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	Iceland	Roche Registration GmbH	20 Sep 2017
Extensive stage Small Cell Lung Cancer	Liechtenstein	Roche Registration GmbH	20 Sep 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Extranodal NK-T-Cell Lymphoma	NDA/BLA	Japan	Chugai Pharmaceutical Co., Ltd.	31 Oct 2024
Bladder Cancer	NDA/BLA	China	Roche Holding AG	25 Feb 2019
Lymphoproliferative Disorders	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Melanoma	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Microsatellite instability-high cancer	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Turcot Syndrome	Phase 3	United Kingdom	Hoffmann-La Roche Ltd.	25 Oct 2023
Muscle Invasive Bladder Carcinoma	Phase 3	Belgium	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Hong Kong	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Mexico	Hoffmann-La Roche, Inc.	03 May 2021
Muscle Invasive Bladder Carcinoma	Phase 3	Singapore	Hoffmann-La Roche, Inc.	03 May 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04256421 (SKYSCRAPER-02, CTgov)	Phase 3	Extensive stage Small Cell Lung Cancer	490	Placebo+Atezolizumab (Placebo + Atezolizumab)	vuxqkxykvz(vinzbktmib) = fwnlvkkvma rcfsnacizf (tsodautkbq, oazrlektrh - rdcrdqxara) View more	-	22 Oct 2025
				Atezolizumab+Tiragolumab (Tiragolumab + Atezolizumab)	vuxqkxykvz(vinzbktmib) = vqqtchtpsh rcfsnacizf (tsodautkbq, rhprdeytxf - wzbhbtpkyd) View more
NCT05694013 (ORIGAMA, CTgov)	Phase 2/3	Neoplasms	49	Atezolizumab (Atezolizumab Regimen)	htynnzzutd(chwywtolzn) = epieudttco gjbaycpeii (lmklzbjixj, bqmwlbmdpi - zirfbyvcue) View more	-	22 Oct 2025
				DPM+Atezolizumab (Atezolizumab Regimen + DPM)	htynnzzutd(chwywtolzn) = djxphomfbz gjbaycpeii (lmklzbjixj, uomhrqpqda - thrfgmqcwq) View more
NCT04543617 (SKYSCRAPER-07, ESMO2025) Manual	Phase 3	Unresectable Esophageal Squamous Cell Carcinoma	760	Tiragolumab + Atezolizumab	sqebkbiczx(iknalvtqwt) = hcmosmjbwz yvlasebeej (jzzhxjamaa, 13.9 - 28.8) View more	Negative	17 Oct 2025
				Atezolizumab + Placebo	sqebkbiczx(iknalvtqwt) = bivgzkfenr yvlasebeej (jzzhxjamaa, 19.0 - 36.3) View more
NCT04513925 (SKYSCRAPER-03, ESMO2025) Manual	Phase 3	PD-L1 positive Non-Small Cell Lung Cancer Consolidation PD-L1 Positive	829	Atezolizumab (atezo) + Tiragolumab (tira)	mxgbjdcuhr(qxgtmeafuh) = yeumnimdjg lownqxnnre (iokebholul, 12.6 - 19.2) View more	Negative	17 Oct 2025
				Durvalumab (durva)	mxgbjdcuhr(qxgtmeafuh) = ziiseadmvr lownqxnnre (iokebholul, 10.9 - 17.0) View more
NCT03598270 (ENGOT-Ov41, ESMO2025)	Phase 3	Recurrent ovarian cancer	332	Atezolizumab + platinum doublet	ffrndfzxiv(dgncuxubzv) = igqqrbwjzl wnuvwoleia (lbolnxfsql ) View more	Positive	17 Oct 2025
				Atezolizumab + platinum doublet	-
NCT03603184 (AtTEnd, ESMO2025)	Phase 3	Endometrial Carcinoma MMRd	234	Atezolizumab + standard chemotherapy (MMRd tumors)	onbwzwtuis(lytpmbwifc): HR = 2.51 (95.0% CI, 1.12 - 5.65), P-Value = 0.0211 View more	Negative	17 Oct 2025
				Placebo + standard chemotherapy
NCT03603184 (AtTEnd, ESMO2025)	Phase 3	Endometrial Carcinoma MMR deficient	549	Atezolizumab + Carboplatin + Paclitaxel	ppxonjxbjy(mgqfkxtayg) = vnossmbaqn zrmrzytcsy (nbbzelgrjc )	Negative	17 Oct 2025
				Placebo + Carboplatin + Paclitaxel	ppxonjxbjy(mgqfkxtayg) = zyocjxdxsy zrmrzytcsy (nbbzelgrjc )
ESMO2025	Not Applicable	Non-Small Cell Lung Cancer gut microbiome	65	Atezolizumab-based immunotherapy (Responders)	ymajkupndm(qmjnafvzen) = Christensenella, Roseburia, Prevotella and Ruminococcus were enriched in R nhyrmwnczj (ctcwqrmpsq ) View more	Positive	17 Oct 2025
				atezolizumab-based immunotherapy (Non-responders)
ESMO2025	Not Applicable	Extensive stage Small Cell Lung Cancer	359	chemotherapy combined with IO (atezolizumab or durvalumab)	upnhyegtzg(efmayzkgvv) = qrlqlmjxmy lqxhtjtgwr (zakdnprszk )	Positive	17 Oct 2025
				platinum-based chemotherapy	upnhyegtzg(efmayzkgvv) = srwacnvkkn lqxhtjtgwr (zakdnprszk )
EUCTR2020-002715-21-DE (ANTONIO, ESMO2025)	Phase 2	Microsatellite instability-high colorectal cancer Neoadjuvant MSI-H \| dMMR \| BRAFV600E	13	Atezolizumab + IMM-101	afgfoppnzl(bgfrbjmegi) = hbxveieidv czjletfqfx (epoxkmghkz ) View more	Negative	17 Oct 2025
				Atezolizumab	zssqpauozc(httrlukzdm) = eqtnyzwpwq mxajqwxtzt (oxjrlygfsw ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis